HistoSonics Secures $102M in Oversubscribed Series D Round to Scale Non-Invasive Histotripsy Platform

HistoSonics has closed an oversubscribed $102 million Series D financing round, led by Alpha Wave Ventures. New investors Amzak Health and HealthQuest Capital joined existing backers Johnson & Johnson Innovation – JJDC, Inc., Venture Investors, Lumira Ventures, Yonjin Venture, and…

Read MoreHistoSonics Secures $102M in Oversubscribed Series D Round to Scale Non-Invasive Histotripsy Platform

DermBiont Unveils SM-020 for Basal Cell Carcinoma and Gorlin Syndrome After Positive Phase 2a Results

DermBiont, a clinical-stage biotech company specializing in innovative topical treatments for rare oncology and dermatology conditions, has reported promising initial results from its open-label, multi-center Phase 2a trial for basal cell carcinoma (BCC). Following these positive findings, DermBiont is shifting…

Read MoreDermBiont Unveils SM-020 for Basal Cell Carcinoma and Gorlin Syndrome After Positive Phase 2a Results

IMFINZI® Granted Priority Review and Breakthrough Therapy Status for Limited-Stage SCLC in the US

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the FDA for Priority Review. This application, based on the positive ADRIATIC Phase III trial results in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease…

Read MoreIMFINZI® Granted Priority Review and Breakthrough Therapy Status for Limited-Stage SCLC in the US

Success Beyond Game Day and XPE Integrate AI Mindset Training into SHREDmill Platform

Success Beyond Game Day and SHREDmill have partnered to integrate AI-driven mindset training into XPE’s SHREDmill platform and online community. This collaboration seeks to elevate the overall development of athletes by incorporating advanced mental training into their speed training programs,…

Read MoreSuccess Beyond Game Day and XPE Integrate AI Mindset Training into SHREDmill Platform

Quince Therapeutics Announces ATTeST Trial Data Publication in The Lancet Neurology

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on utilizing patients’ own biology to treat rare diseases, has announced the online publication of data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial in…

Read MoreQuince Therapeutics Announces ATTeST Trial Data Publication in The Lancet Neurology

Concentra Expands Telemedicine to Include Behavioral Health for Workers’ Comp

Concentra®, a leading provider of occupational medicine, has announced the introduction of its new behavioral health service on Concentra Telemed®, the company’s telemedicine platform for workers’ compensation. Concentra® has introduced a behavioral health service to its Concentra Telemed® platform, enhancing…

Read MoreConcentra Expands Telemedicine to Include Behavioral Health for Workers’ Comp